140 related articles for article (PubMed ID: 30580302)
21. Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report.
Nawashiro Y; Shiraki K; Yamamoto S; Takizawa K; Sasada Y; Suehiro M; Miura K; Hattori M; Daikoku T; Hisano M
Transplant Proc; 2018 Dec; 50(10):3932-3936. PubMed ID: 30577289
[TBL] [Abstract][Full Text] [Related]
22. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.
Manuel O; Perrottet N; Pascual M
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):955-65. PubMed ID: 22029513
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus infection in immunocompetent and immunocompromised individuals--a review.
Vancíková Z; Dvorák P
Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):179-87. PubMed ID: 12476798
[TBL] [Abstract][Full Text] [Related]
24. Editorial commentary: Use of valganciclovir for prevention and treatment of cytomegalovirus disease.
Snydman DR
Clin Infect Dis; 2008 Jan; 46(1):28-9. PubMed ID: 18171209
[No Abstract] [Full Text] [Related]
25. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
27. [Valganciclovir. Oral treatment of Cytomegalovirus infections].
Kroes AC
Ned Tijdschr Geneeskd; 2004 Jun; 148(25):1236-8. PubMed ID: 15301386
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
29. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
Razonable RR; Paya CV
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
[TBL] [Abstract][Full Text] [Related]
30. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
Grossi P; Mohacsi P; Szabolcs Z; Potena L
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
[TBL] [Abstract][Full Text] [Related]
33. Atypical presentation of CMV pneumonia in a heart transplant patient.
Boussouar S; Campedel L; Noble PD; Turki MW; Calvo J; Pourcher V; Rolland-Debord C
Med Mal Infect; 2018 Mar; 48(2):151-153. PubMed ID: 29329823
[No Abstract] [Full Text] [Related]
34. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease.
Mizukawa Y; Hirahara K; Kano Y; Shiohara T
J Am Acad Dermatol; 2019 Mar; 80(3):670-678.e2. PubMed ID: 30240780
[TBL] [Abstract][Full Text] [Related]
35. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
Gilbert C; LeBlanc MH; Boivin G
Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
[TBL] [Abstract][Full Text] [Related]
36. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
37. Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.
Deback C; Burrel S; Varnous S; Carcelain G; Conan F; Aït-Arkoub Z; Autran B; Gandjbakhch I; Agut H; Boutolleau D
Antivir Ther; 2015; 20(2):249-54. PubMed ID: 25219330
[TBL] [Abstract][Full Text] [Related]
38. Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation.
Sood S; Haifer C; Yu L; Pavlovic J; Gow PJ; Jones RM; Visvanathan K; Angus PW; Testro AG
Transpl Infect Dis; 2018 Oct; 20(5):e12934. PubMed ID: 29809312
[TBL] [Abstract][Full Text] [Related]
39. Impairment of cytomegalovirus-specific cellular immune response as a risk factor for cytomegalovirus disease in transplant recipients.
Motta VN; Martins SL
Braz J Med Biol Res; 2008 Jan; 41(1):5-11. PubMed ID: 18060322
[TBL] [Abstract][Full Text] [Related]
40. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
Davoudi S; Kasraianfard A; Ahmadinejad Z; Najafi A; Salimi J; Makarem J; Sohrabpour AA; Jafarian A
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():72-5. PubMed ID: 24635797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
